ArticleOncogene2026
MCM2 germline variants predispose to familial papillary thyroid carcinoma due to genomic instability caused by MCM complex disruption.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In recent years, new cases of thyroid cancer (TC) in China have accounted for about 10% of all newly diagnosed malignant tumors, ranking as the third most common cancer. Familial papillary thyroid carcinoma (fPTC) is a hereditary subtype for which large-scale clinical cohort studies are lacking and definitive susceptibility genes remain elusive. A large fPTC clinical cohort (171 cases), 490 sporadic papillary thyroid carcinoma (sPTC) patients, and 500 healthy blood samples from physical examination were collected in the study. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) were used to screen for susceptibility genes. Three MCM2 gene mutations (c.1092 C > G, p.N364K; c.1975A>G, p.I659V; and c. 2379 G > A, p.M793I) in 8 patients from 4 distinct families were identified as candidate susceptibility variants. These mutations disrupt the interaction of MCM2 with its partner proteins (MCM3-7), leading to ubiquitination of free MCM monomers. Levels of DNA damage, γ-H2AX foci, RPA foci, and micronucleus formation were significantly elevated in MCM2-deficient cells. Cell-derived xenograft (CDX) modeling, combined with WES and RNA-seq analyses, revealed that MCM2-deficient tumors exhibited significantly faster growth rates and increased chromosomal instability (CIN). MAPK signaling and the PI3K-AKT pathway were significantly over-activated in MCM2-deficient tumors. In our study, based on the fPTC cohort, germline variants of MCM2 predispose to fPTC. The variants disrupt the MCM complex, leading to ubiquitination of free monomeric MCM proteins. MCM2 deficiency induces cell cycle arrest, DNA damage, and CIN, ultimately accelerating tumorigenesis through oncogenic pathway activation. These findings identify MCM2 as a low-frequency, moderately penetrant susceptibility gene for fPTC and underscore the clinical value of MCM2 testing in informing early detection, preventive management, and precision treatment strategies for familial papillary thyroid carcinoma.
Indexed as
Identifiers
42315912What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.